Cases and Controversies in HIV in 2019: A European Perspective
  • CME
  • CE

Watch this CME-certified video to learn unique perspectives across Europe on PrEP, rapid ART initiation, ART in women, and options for switching ART.
Esteban Martínez, MD, PhD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Jürgen K. Rockstroh, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
Registered Nurses: 1.7 Nursing contact hours
Pharmacists: 1.75 contact hours (0.175 CEUs)
Released: September 4, 2019 Expiration: September 3, 2020
Multimedia Cases and Controversies in HIV in 2019: A European Perspective
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Case 1: Rapid ART Initiation
Review the panel’s approaches to same-day or same-week ART starts
Launch Case 1: Rapid ART Initiation
Case 2: ART in Woman of Childbearing Age
Consider the panel’s recommendations for women in light of new data
Launch Case 2: ART in Woman of Childbearing Age
Case 3: Switching a Patient With Low-Level Viremia and Viral Resistance
Hear the panel’s perspectives on ART choices
Launch Case 3: Switching a Patient With Low-Level Viremia and Viral Resistance
Case 4: Switching a Patient With Virologic Suppression and Comorbidities
Find out how comorbidities affect the panel’s treatment decisions
Launch Case 4: Switching a Patient With Virologic Suppression and Comorbidities
Case 4: Continued: Long-Acting ART
Hear about this emerging switch option
Launch Case 4: Continued: Long-Acting ART
Case 5: PrEP
Review PrEP considerations, evidence, and perspectives from the panel
Launch Case 5: PrEP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the results of recent clinical studies and evolving treatment guidelines on the timing and choice of first-line ART and switch strategies, and managing treatment-experienced HIV-infected patients
  • Effectively prevent or manage drug–drug interactions, adverse events, and other complications associated with HIV, ART, and comorbidities
  • Apply evidence-based strategies for the use of ART as prevention

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
ViiV Healthcare

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has disclosed that she has received funds for research support, consulting fees, and fees for non-CME/CE services from Gilead Sciences, GlaxoSmithKline, Janssen, MSD, and ViiV.
Esteban Martínez, MD, PhD

Team Leader Consultant & Associate Professor of Medicine
Infectious Diseases Unit
Hospital Clinic of Barcelona
University of Barcelona
Barcelona, Spain

Esteban Martínez, MD, PhD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, MSD, and ViiV and funds for research support from MSD and ViiV.
Jürgen K. Rockstroh, MD

Professor of Medicine
University of Bonn
Bonn, Germany

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Gilead Sciences, Janssen, Merck, and ViiV and fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, Merck, and ViiV.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for HIV specialists, infectious diseases clinicians, hepatologists, gastroenterologists, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with HIV infection and/or viral hepatitis.

Goal

The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in HIV management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.7 contact hours may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-097-H02-P. This program is designated for up to 1.75 contact hours (0.175 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 04, 2019, through September 03, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Clinical Care Options’ expert audio on managing heavily treatment-experienced patients with HIV by Joseph J. Eron, Jr., MD, and Paul E. Sax, MD

Joseph J. Eron, Jr., MD Paul E. Sax, MD Released: October 15, 2019

Expert commentary from Babafemi Taiwo, MBBS, on less frequent dosing regimens offered by investigational HIV drugs in the prevention and treatment pipeline

Babafemi Taiwo, MBBS Released: October 10, 2019

Expert commentary from Jonathan Colasanti, MD, about the challenges and successes of instituting rapid ART in the Grady Health System in Atlanta

Jonathan Colasanti, MD, MSPH Released: October 9, 2019

Clinical Care Options’ slideset on managing heavily treatment experienced patients with HIV by Joseph J. Eron, Jr., MD, and Paul E. Sax, MD

Joseph J. Eron, Jr., MD Paul E. Sax, MD Released: October 7, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?